🔴 Adaptive Biotechnologies Corp is trading 4.2% down today on profit-taking after a multi-day rally on positive clonoSEQ data

Adaptive Biotechnologies Corp is trading at $17.95, down 4.2% today as the stock undergoes consolidation following a significant multi-day rally.

• The recent surge was driven by positive clinical results for the clonoSEQ minimal residual disease testing platform presented at the EHA 2026 Congress.
• Today's price action appears to be a natural pullback and profit-taking rather than a response to any new negative company-specific developments.
• The stock remains elevated relative to previous weeks, supported by an improved outlook following the clinical data presentation.